(Q37610078)

21 August 2017

First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile (English)

1 reference

metastatic renal cell carcinoma

21 August 2017

0 references

1 reference

1 reference

Elena Verzoni

2

0 references

Giuseppe Procopio

object named as

Giuseppe Procopio

series ordinal

4

0 references

Filippo de Braud

object named as

Filippo De Braud

series ordinal

3

0 references

Roberto Iacovelli

series ordinal

1

object named as

Roberto Iacovelli

1 reference

21 August 2017

19 November 2013

1 reference

Cancer Biology and Therapy

21 August 2017

1 reference

21 August 2017

15

1 reference

21 August 2017

1

1 reference

21 August 2017

19-21

1 reference

Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Past, present and future of targeted therapy in solid tumors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

Global estimates of cancer prevalence for 27 sites in the adult population in 2008.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3938518

6 September 2017

Identifiers

DOI

10.4161/CBT.27150

1 reference

21 August 2017

1 reference

PMC publication ID

3938518

21 August 2017

PubMed publication ID

24253418

1 reference

PMC publication ID

3938518